🇺🇸 Latanoprost bunod 0.024% in United States

FDA authorised Latanoprost bunod 0.024% on 2 November 2017

Marketing authorisations

FDA — authorised 2 November 2017

  • Application: NDA207795
  • Marketing authorisation holder: BAUSCH AND LOMB
  • Local brand name: VYZULTA
  • Indication: SOLUTION/DROPS — OPHTHALMIC
  • Status: approved

Read official source →

FDA

  • Status: approved

Latanoprost bunod 0.024% in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Latanoprost bunod 0.024% approved in United States?

Yes. FDA authorised it on 2 November 2017; FDA has authorised it.

Who is the marketing authorisation holder for Latanoprost bunod 0.024% in United States?

BAUSCH AND LOMB holds the US marketing authorisation.